Akorn (AKRX) Receives Daily Media Sentiment Rating of 0.17

News articles about Akorn (NASDAQ:AKRX) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akorn earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6922411492349 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Shares of Akorn (NASDAQ AKRX) traded down $0.01 during trading hours on Friday, reaching $33.55. 1,240,074 shares of the company traded hands, compared to its average volume of 1,400,000. The firm has a market capitalization of $4,200.00, a PE ratio of 56.86, a price-to-earnings-growth ratio of 1.73 and a beta of 1.33. Akorn has a 52-week low of $17.74 and a 52-week high of $34.00. The company has a current ratio of 4.16, a quick ratio of 3.17 and a debt-to-equity ratio of 0.92.

Several analysts have recently issued reports on AKRX shares. Jefferies Group set a $34.00 price target on shares of Akorn and gave the stock a “hold” rating in a research report on Sunday, October 29th. Zacks Investment Research raised shares of Akorn from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 price target on shares of Akorn and gave the stock a “hold” rating in a research report on Sunday, October 22nd. Royal Bank of Canada reissued a “hold” rating and set a $34.00 price target on shares of Akorn in a research report on Tuesday, October 3rd. Finally, BidaskClub raised shares of Akorn from a “strong sell” rating to a “sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. The stock has an average rating of “Hold” and an average target price of $29.17.

In related news, Director Brian Tambi sold 15,100 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total value of $503,585.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 28.20% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2018/01/13/akorn-akrx-receives-daily-media-sentiment-rating-of-0-17.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Insider Buying and Selling by Quarter for Akorn (NASDAQ:AKRX)

What are top analysts saying about Akorn? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akorn and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit